TiGenix NV (LSE:0EIT) - Share price - Overview

Stock Report

TiGenix NV 0EIT

Last Price
-

Day Change
-|-%

As of -
- | EUR
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap523.40Mil
52-Wk Range-
Yield %-
ISINBE0003864817
Volume-
P/E-
P/S-
P/CF-

Share Price

Total Returns 24/05/2018

 Chg (%)  
More ...
TiGenix NV1.25 
FTSE 100 TR GBP4.27
 
Financials
201520162017
More ...
Income Statement
Turnover2.2426.790.91
Operating Profit-24.08-3.03-53.18
Net Profit-35.073.80-74.83
Reported EPS-0.210.02-0.28
Balance Sheet
Current Assets24.9384.1239.47
Non Current Assets54.2452.0842.42
Total Assets79.17136.2081.90
Current Liabilities13.8920.1355.47
Total Liabilities66.0356.5260.53
Total Equity13.1579.6821.37
Cash Flow
Operating Cash Flow-19.572.40-31.81
Net Change in Cash4.5259.99-43.91

Company Profile

TiGenix NV is a biopharmaceutical company. It exploits anti-inflammatory properties of stem cells to develop therapies from its proprietary technology platforms for serious medical conditions in the areas of high unmet medical need.

Sector

Biotechnology

Index

Next Event 01/06/2018

Annual General Meeting
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-255.98
Op Mrgn-58.70
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2018 Morningstar. All rights reserved.